Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company specializing in dermatology and photodynamic therapy (PDT). Its news flow centers on the commercialization and clinical development of Ameluz® and the RhodoLED® lamp series for the treatment of actinic keratoses and other skin conditions.
On this page, readers can follow company announcements related to financial results, such as quarterly and annual revenue updates, as well as business updates describing trends in Ameluz® sales and operating expenses. Biofrontera frequently reports on revenue performance, gross margin developments, and the impact of its strategic agreements on its financial profile.
News items also highlight clinical and regulatory milestones. These include database locks and completion of clinical studies in actinic keratosis on peripheral body areas, Phase 1 pharmacokinetics data, Phase 3 results in superficial basal cell carcinoma, and Phase 2 progress in acne vulgaris. The company uses press releases to describe how these data support supplemental New Drug Applications and future Phase 3 programs.
In addition, Biofrontera issues updates on strategic transactions and capital markets activity, such as the acquisition of all U.S. rights to Ameluz® and RhodoLED® from Biofrontera AG, changes to royalty and earnout structures, private placements of convertible preferred stock, and the divestiture of its Xepi® antibiotic cream license. Regulatory notices regarding Nasdaq listing compliance and participation in investor conferences are also part of the company’s regular news flow.
Investors and observers who want to track developments in dermatologic photodynamic therapy, label expansion efforts for Ameluz®-PDT, and Biofrontera’s financial and strategic progress can use this news feed as a centralized source of company-issued updates.
Biofrontera Inc. (Nasdaq: BFRI) will announce its financial results for the three and nine months ending September 30, 2021, before the U.S. markets open on November 30, 2021. The company will host a conference call that day at 4:30 p.m. Eastern time to discuss the results and provide a business update. Biofrontera specializes in dermatological products and focuses on treating conditions such as actinic keratoses and impetigo. Investors can access the live webcast and replay on their website.
Biofrontera Inc. (BFRI) has initiated a clinical study program to optimize its FDA-approved drug, Ameluz®, for photodynamic therapy in the U.S. Two studies are set to begin recruiting patients before year-end, focusing on treating moderate-to-severe acne and assessing safety with multiple tubes of Ameluz®. Under a licensing agreement with Biofrontera AG, the company holds exclusive marketing rights. Ameluz® is crucial for Biofrontera's growth in the U.S. dermatological market, aiming to enhance its positioning against actinic keratosis.
Biofrontera Inc. announced the closing of its initial public offering on November 2, 2021, raising $18 million by issuing 3,600,000 units, each comprising one common share and one warrant, priced at $5.00 per unit. The offering was successful, with underwriters exercising an option for an additional 540,000 warrants. These warrants are exercisable over five years at the same price. Biofrontera's common stock and warrants trade under the symbols BFRI and BFRIW respectively.
Biofrontera Inc. (Nasdaq: BFRI) announced its initial public offering (IPO) of 3,600,000 units, each priced at $5.00, consisting of one share of common stock and one warrant. The offering could generate $18 million in gross proceeds, before deducting fees. A 30-day option allows underwriters to purchase an additional 540,000 shares. Trading for these securities is set to start on October 29, 2021, with the offering closing expected on November 2, 2021.